Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con
about
The PCSK9 decadeLDL cholesterol, statins and PCSK 9 inhibitorsPCSK9 and triglyceride-rich lipoprotein metabolismNew drugs for treating dyslipidemia: beyond statinsStatins: definitive translational researchNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsGenetics of lipid traits and relationship to coronary artery diseaseProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseaseNew Era of Lipid-Lowering DrugsPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaHuman genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathwayModulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expressionInflammation modulation and cardiovascular disease prevention.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaNew frontiers in the treatment of diabetic dyslipidemiaEfficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Quality of diabetes care in primary health centres in north Al-batinah of oman.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Familial hypercholesterolemia: developments in diagnosis and treatmentAlirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.Proprotein convertases in high-density lipoprotein metabolism.Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin.A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic PopulationsA randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 antibodies for the treatment of hypercholesterolemiaEfficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS SGene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector.Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats.Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase
P2860
Q24615397-86100DE7-1880-468B-A2C5-449C51A05485Q26782522-AE9AB405-7D33-4E5B-A44B-D5247416B7BFQ26796287-03609370-41B5-40CD-96C4-6E77037A992DQ26821840-7E7F6768-5DD8-47D6-8F16-D36ECD659132Q26851528-D5E07D12-8663-4CF0-8AFE-9F49A252953BQ26863369-49A2FE7A-9F26-4090-A546-3DA9E13D30A1Q26995252-AC5EBE90-B699-4E88-9781-E1602A1B4E1CQ27009477-B9E71468-BC7C-4EF4-9C49-2E769D5719F2Q28070296-36837A32-CFF6-446C-9138-AE88D096462FQ28071452-9B18E454-BFD3-4AFF-8815-BD4CFAAE485FQ28072298-3176A8C8-2C36-4CA4-A059-0C5B12E5C56DQ28275648-302047B4-3AEC-48F9-87DD-197B223F6FE6Q28488150-F601AAA8-F54A-47D1-AEDE-D739CBA0D260Q28545029-32515B87-1F03-4ECE-8E48-65CAD93F8C41Q30361151-F9BE7BA4-D973-41A7-AE21-97CE1768A11EQ30833167-1D63DF2E-E135-4E1B-905B-542FFFE43BBDQ33670893-52BA180B-684F-4EF6-8294-662B3CD50A1EQ33728343-E90440BB-0219-4B7F-A04C-041F82964450Q33776236-33AF2089-AC6D-49F4-9FB6-FA7E6C197530Q33808620-4D21A5F8-3CDB-4223-AE79-A9091D81EAD1Q33818871-A8B0BFC9-E5DE-496E-8E33-C49952A7D96DQ33886785-859013D1-F9C2-46CC-8238-C7AF3E553089Q33904455-E761FA24-BE62-44B9-98BB-6D19135A0588Q34035025-50F747ED-9D26-41E9-907E-FB88DB68B2DEQ34071937-521FEE35-FC9C-4DCF-B8CA-D7152A5CCA5DQ34106665-EA8FA308-404B-4B82-9D3D-294FB1093D2AQ34238694-91D42FD4-8E11-4A64-9188-91C64EF446D7Q34256139-188461CD-3203-404B-A314-F2854C56C0F4Q34321484-34EBC412-E690-415E-950E-EC94C48A0267Q34458693-30C6C49E-FDBF-4AED-B21C-C38C03D89BB6Q34588435-825BD850-4618-4673-A219-ABE314DE2258Q34658086-B8A34A86-659B-4521-91ED-8702CEB0B1B3Q34669942-884C286D-29D4-4079-AF22-D1C841BB9770Q34723257-862ED85B-1D86-464B-BE0B-E3993518D366Q34774969-10C5CE4E-028F-4813-B6EF-B0E274C152B1Q34805650-14889BF0-C86B-41AA-A571-55A2708CD824Q34892789-04148875-AC4B-45E9-B907-FEEAFA4DCEE6Q35111400-0020D4E5-F7D9-48CE-8CD9-4645736AF3BDQ35132715-EAFC0386-DDDE-4EC5-A9CE-81B30AD7429AQ35141476-39A3139C-D5D4-43FB-8195-37EFFDC41451
P2860
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@en
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@nl
type
label
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@en
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@nl
prefLabel
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@en
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@nl
P2093
P921
P1433
P1476
Effect of a monoclonal antibod ...... rapy: a phase 2 randomised con
@en
P2093
Daniel Gaudet
Evan A Stein
Jean Bergeron
Richard Wu
Robert Dufour
Robert Pordy
Robert Weiss
P356
10.1016/S0140-6736(12)60771-5
P407
P577
2012-05-26T00:00:00Z